Kyverna Therapeutics, Inc.'s total assets for Q4 2025 were $293.83M, an increase of 57.00% from the previous quarter. KYTX total liabilities were $61.55M for the fiscal quarter, a 74.81% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.